235 related articles for article (PubMed ID: 11118465)
1. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.
Chappuis PO; Kapusta L; Bégin LR; Wong N; Brunet JS; Narod SA; Slingerland J; Foulkes WD
J Clin Oncol; 2000 Dec; 18(24):4045-52. PubMed ID: 11118465
[TBL] [Abstract][Full Text] [Related]
2. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Chappuis PO; Donato E; Goffin JR; Wong N; Bégin LR; Kapusta LR; Brunet JS; Porter P; Foulkes WD
Ann Oncol; 2005 May; 16(5):735-42. PubMed ID: 15802279
[TBL] [Abstract][Full Text] [Related]
3. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
Foulkes WD; Chappuis PO; Wong N; Brunet JS; Vesprini D; Rozen F; Yuan ZQ; Pollak MN; Kuperstein G; Narod SA; Bégin LR
Ann Oncol; 2000 Mar; 11(3):307-13. PubMed ID: 10811497
[TBL] [Abstract][Full Text] [Related]
4. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
5. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383
[TBL] [Abstract][Full Text] [Related]
6. BRCA-associated breast cancer in young women.
Robson M; Gilewski T; Haas B; Levin D; Borgen P; Rajan P; Hirschaut Y; Pressman P; Rosen PP; Lesser ML; Norton L; Offit K
J Clin Oncol; 1998 May; 16(5):1642-9. PubMed ID: 9586873
[TBL] [Abstract][Full Text] [Related]
7. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
8. The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
Kreiss Y; Barak F; Baruch RG; Levy-Lahad E; Pras E; Friedman E
Genet Test; 2000; 4(4):403-7. PubMed ID: 11216667
[TBL] [Abstract][Full Text] [Related]
9. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
[TBL] [Abstract][Full Text] [Related]
11. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B
Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
[TBL] [Abstract][Full Text] [Related]
12. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
[TBL] [Abstract][Full Text] [Related]
13. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ; Sahin AA; Rassidakis GZ; Yuan LX; Smith TL; Yang Y; Gilcrease MZ; Cristofanilli M; Nahta R; Pusztai L; Claret FX
Clin Cancer Res; 2003 Nov; 9(15):5652-9. PubMed ID: 14654548
[TBL] [Abstract][Full Text] [Related]
14. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
Pierce LJ; Strawderman M; Narod SA; Oliviotto I; Eisen A; Dawson L; Gaffney D; Solin LJ; Nixon A; Garber J; Berg C; Isaacs C; Heimann R; Olopade OI; Haffty B; Weber BL
J Clin Oncol; 2000 Oct; 18(19):3360-9. PubMed ID: 11013276
[TBL] [Abstract][Full Text] [Related]
15. Risk of endometrial carcinoma associated with BRCA mutation.
Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J
Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938
[TBL] [Abstract][Full Text] [Related]
16. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
17. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.
Gershoni-Baruch R; Dagan E; Fried G; Bruchim Bar-Sade R; Sverdlov-Shiri R; Zelicksson G; Friedman E
Eur J Cancer; 2000 May; 36(8):983-6. PubMed ID: 10885601
[TBL] [Abstract][Full Text] [Related]
18. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
[TBL] [Abstract][Full Text] [Related]
19. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
[TBL] [Abstract][Full Text] [Related]
20. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]